title: Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial.
abstract: OBJECTIVE
  Depression is a debilitating complication of brucellosis and how best to treat this is a matter of debate. Inflammatory processes are involved in the pathogenesis of both brucellosis and depression. Therefore, we hypothesized that celecoxib could be beneficial for the treatment of depression due to brucellosis.
  
  
  METHODS
  Forty outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19 participated in a randomized, double-blind, placebo-controlled trial and underwent 8 weeks of treatment with either celecoxib (200 mg bid) or placebo as an adjunctive to antibiotic therapy. Patients were evaluated using HDRS at baseline and weeks 4 and 8.
  
  
  CONCLUSIONS
  Repeated-measures analysis demonstrated significant effect for time × treatment interaction on the HDRS score [F (1·43, 57·41) = 37·22, P < 0·001]. Significantly greater response to treatment occurred in the celecoxib group than in the placebo group at the study end [10 patients (50%) vs. no patient (0%), respectively, P < 0·001]. No serious adverse event was observed.
  
  
  CONCLUSIONS
  Celecoxib is a safe and effective treatment for depression due to brucellosis when compared with placebo.
authors.affiliation: Department of Infectious Diseases, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: S
authors.initials: S
authors.lastname: Jafari
authors.affiliation: Department of Infectious Diseases, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: S-G
authors.initials: SG
authors.lastname: Ashrafizadeh
authors.affiliation: Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: A
authors.initials: A
authors.lastname: Zeinoddini
authors.affiliation: Department of Infectious Diseases, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: M
authors.initials: M
authors.lastname: Rasoulinejad
authors.affiliation: Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: P
authors.initials: P
authors.lastname: Entezari
authors.affiliation: Imam Hospital, Ilam University of Medical Sciences, Ilam, Iran.
authors.forename: S
authors.initials: S
authors.lastname: Seddighi
authors.affiliation: Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: S
authors.initials: S
authors.lastname: Akhondzadeh
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002006:Brucellosis / Q000188:drug therapy / Q000523:psychology*; D000068579:Celecoxib / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000928:Antidepressive Agents; D052246:Cyclooxygenase 2 Inhibitors; D000068579:Celecoxib
keywords: brucellosis; celecoxib; clinical trial; depression; inflammation